Navigation Links
New Effort to Battle Antibiotic Resistance Rallies Researchers Throughout Harvard University
Date:10/13/2009

BOSTON, Oct. 13 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) have awarded $5 million to an interdisciplinary group of Harvard researchers to launch the "Harvard-wide Program on Antibiotic Resistance." Headed by Michael S. Gilmore, Ph.D., (Senior Scientist, Schepens Eye Research Institute and Schepens Professor of Ophthalmology [Department of Microbiology and Molecular Genetics], HMS), the group is uniting Harvard institutions in the fight against methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic resistant infection. The goal of the project is for the research team with a range of expertise to tackle the problem from different directions, and then to translate those findings into better treatments.

It shocked many a year and a half ago when CDC researchers noted that methicillin-resistant S. aureus (MRSA) were killing more in the US than HIV/AIDS (over 18,000 deaths per year). According to Gilmore, other penicillin resistant strains of S. aureus cause almost half again as many deaths. Worse, since 2002, MRSA have been acquiring resistance to one of the last line drugs used to treat those infections, vancomycin, a problem he has been studying with scientists at CDC.

MRSA are a major concern for hospitalized patients. More recently they have begun causing infections in healthy individuals in the community as well -- approximately 15% of invasive MRSA infections occur in patients with no known underlying cause. Most of these infections begin as skin infections, some acquired in sports locker rooms and other shared facilities. The infections become life-threatening when the microbe enters the bloodstream. New strains of MRSA have emerged that are causing many of the community infections.

Gilmore credits the Harvard-wide Microbial Sciences Initiative (an initiative launched in 2004 to bring together microbiology researchers from all Harvard campuses), the Harvard Catalyst Clinical and Translational Science Center, and a Schepens program to launch interdisciplinary research projects, for bringing this team together.

"We have been friends and collaborators on this important problem and also the new interdisciplinary and translational efforts on campus. Formalizing these relationships was a small and logical step that each of us embraced. We were lucky that all of the pieces fell into place so well," said Gilmore.

Working with molecular microbiologist Gilmore are: David Hooper, MD (Associate Chief of Infectious Diseases and Head of Infection Control, MGH and Professor of Medicine, HMS); Suzanne Walker, Ph.D. (Professor of Microbiology and Molecular Genetics, HMS); Eleftherios Mylonakis, MD, Ph.D (Assistant Professor of Medicine, HMS and Member, Infectious Diseases, MGH); and Frederick M. Ausubel, Ph.D., Professor of Genetics HMS, and Member, Molecular Biology, MGH).

Walker, Mylonakis and Ausubel will be taking different high-throughput approaches to screen libraries of compounds for possible new drugs. Gilmore, Hooper and Mylonakis will then test these compounds for their ability to clear an infection, and will also examine possible pathways for the development of resistance. These projects will additionally benefit from input from, Richard Losick, Ph.D. (Harvard College Professor and Maria Moors Cabot Professor of Biology), who will assist Gilmore on his subproject, as well as head an advisory panel.

Other world leaders in the area of antibiotic resistance who will be members of the advisory panel are Christopher T. Walsh, Ph.D., (Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology, HMS); Jared Silverman, Ph.D. (Senior Director, In Vitro Biology, Cubist Pharmaceuticals, Inc.), and Steven J. Projan, Ph.D (Vice President and Global Head, Infectious Diseases, Novartis Pharmaceuticals, Inc.). "The involvement of thought leaders from the pharmaceutical industry will be an important key to the ultimate translation of the results of this project," according to Gilmore.

More information on this project can be obtained by email: Antibiotic.Resistance@schepens.harvard.edu

Schepens Eye Research Institute is an affiliate of Harvard Medical School and the largest independent eye research institute in the country.

SOURCE Schepens Eye Research Institute


'/>"/>
SOURCE Schepens Eye Research Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts
2. Argonauta Assist(TM)ance: Argonauta Communications Strives to Enhance Site-Based Recruitment Efforts
3. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
4. Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection
5. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
6. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
7. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
8. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
9. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
10. Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup
11. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today ... test for wounds and infections. This test ensures ... and select viruses. The test requires only a ... David G. Bostwick , MD, ... to facilitate wound healing: "We are excited to ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... ... a year and a half of planning the Multiple Pathways of Recovery Conference , ... Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel & ... explore the many pathways individuals use to get into and sustain their recovery. Pathways ...
(Date:5/27/2016)... ... 2016 , ... More than a third of American adults are considered obese, ... has received increased attention in recent years, as an article published May ... loss, most people are familiar with the basic requirements of maintaining a healthy diet ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue ... Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in ... Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon ...
(Date:5/27/2016)... ... ... An influential resource amongst nurses and professionals in the health care world, ... of topics detailing why we appreciate nurses in so many different ways. From exclusive ... being in a major recession to one of the hottest growing professions in any ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to ... which we as a society can control and change. , As nearly 795,000 Americans ... 40 seconds within the United States. Plus, with an estimated 129,000 of these people ...
Breaking Medicine News(10 mins):